Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
12.52
-0.04 (-0.32%)
At close: Dec 31, 2025, 4:00 PM EST
12.28
-0.24 (-1.92%)
After-hours: Dec 31, 2025, 5:30 PM EST
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Trevi Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $20.38, which forecasts a 62.78% increase in the stock price over the next year. The lowest target is $12.5 and the highest is $27.
Price Target: $20.38 (+62.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 8 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $15 → $18 | Strong Buy | Maintains | $15 → $18 | +43.77% | Dec 19, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $13 → $16 | Buy | Maintains | $13 → $16 | +27.80% | Nov 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +51.76% | Nov 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $23 → $24 | Buy | Maintains | $23 → $24 | +91.69% | Nov 14, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $19 | Buy | Maintains | $18 → $19 | +51.76% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.37
from -0.47
EPS Next Year
-0.48
from -0.37
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.37 | -0.23 | ||||
| Avg | -0.37 | -0.48 | ||||
| Low | -0.40 | -0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.